TVM Capital Life Science
Hubert Birner is currently serving as the Managing Partner/Geschäftsführer at TVM Capital since October 2000. Prior to that, Hubert worked at Zeneca Agrochemicals from 1999 to 2000 as the Head of Business Development Europe/Germany. Before that, Hubert was a Management Consultant at McKinsey & Company Deutschland from 1995 to 1999. Hubert Birner also worked as a Universitätsdozent at Ludwig-Maximilians Universität München from 1991 to 1994. Hubert holds a Master of Business Administration (MBA) from Harvard Business School (1994-1996) and a Staatsexamen/Approbation/Promotion in Veterinärmedizin from Ludwig-Maximilians-Universität München (1986-1991).
TVM Capital Life Science
TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.